Ivantist Treats Glaucoma
Ivantis Microstent Technology
Ivantis MicroStent News & Events
Contact Ivantis Microstent Developers

Ivantis Microstent Eligibility Program

Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.

What's New

Ivantis Raises Additional $5 MM from Singapore-based Global Investor, EDBI, Increasing Series B to $32.5 MM (August, 2013)

Micro-stents progressively defining their role in glaucoma management (July, 2013)

Ivantis blue ribbon award

Ivantis Wins "Best of Session" Award at ASCRS

Ivantis recently won a Blue Ribbon award for our presentation on the use of Hydrus Technology. See it by clicking here.